Translational research requires access to appropriately consented and well-characterized human biosamples. Therefore, the Fox Chase Cancer Center (FCCC) established the Biosample Repository Core Facility (BRCF) in 1999/2000 to support this research. The BRCF is a CAP accreditation and CLIA-approved Facility that has two major functions: 1) BRCF staff identifies participants, administers informed consent for blood and tissue use, and collects blood samples and information on personal and family histories of cancer, clinical intervention, clinical outcomes, and lifestyle factors for use in research, and 2) BRCF staff processes and houses human biospecimens obtained through investigator-initiated studies. The FCCC has many funded research Programs which require access to biospecimens from large cohorts of properly consented individuals affected and unaffected with cancer. Programs include: i) clinical studies to assess genetic susceptibility in cancer prone-kindreds, ii) large scale genotyping studies to identify genetic modifiers of cancer risk, iii) pharmacogenomic studies to identify drug response and drug toxicity markers, iv) hormone and immune response studies to determine the role of psychological stress and breast cancer risk, v) smoking cessation studies using genetic modifiers to assess behavioral response, vi) hormone and genotype studies to predict cancer risks, vii) identifying plasma membrane proteins that are selectively expressed in lung or prostate cancer to identify new targets for the development of additional therapeutic monoclonal antibodies, and viii) studies of early detection of cancer by genetic, epigenetic, and proteomic approaches. The BRCF provides a centralized service for accrual, consenting, processing, banking, and/or distribution of human blood samples (e.g., whole blood, plasma, serum, platelet-rich plasma, platelet homogenates, red blood cells, leukocytes, lymphoblastoid cell lines, and DNA) and cancer history data to be utilized in genetic-, epigenetic-, and proteomic-related research. The BRCF currently houses more than 300,000 human biosamples and has served 28 (26 peer-reviewed funded) Fox Chase investigators across 12 Programs and the three Divisions since its inception at the time of previous Core renewal. Ninety-six percent (96%) of the BRCF's use is by peer-reviewed funded investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-46
Application #
7651459
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
46
Fiscal Year
2008
Total Cost
$168,355
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298
Mishra, Om P; Popov, Anatoliy V; Pietrofesa, Ralph A et al. (2018) Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits myeloperoxidase activity in inflammatory cells. Biochim Biophys Acta Gen Subj 1862:1364-1375
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142

Showing the most recent 10 out of 1280 publications